Get the Stockscreener App
29.29
8.52%
2.30
After Hours:
29.00
-0.29
-0.99%
Oruka Therapeutics Inc stock is traded at $29.29, with a volume of 397.32K.
It is up +8.52% in the last 24 hours and up +7.05% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$26.99
Open:
$26.9
24h Volume:
397.32K
Relative Volume:
0.98
Market Cap:
$1.42B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.16%
1M Performance:
+7.05%
6M Performance:
+176.84%
1Y Performance:
+42.88%
1-Day Range:
$26.52
$29.69
1-Week Range:
$26.52
$29.87
52-Week Range:
$5.485
$29.98
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
29.29 | 1.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Does Oruka Therapeutics Inc. stock trade at a discount to peersJuly 2025 Volume & Weekly Market Pulse Alerts - newser.com
Jefferies Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Can Oruka Therapeutics Inc. (HQ1) stock hit consensus price targetsWeekly Trade Review & Capital Protection Trading Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock rise with strong economyRate Cut & High Accuracy Trade Signal Alerts - newser.com
Is Oruka Therapeutics Inc. stock attractive for income investorsQuarterly Investment Review & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-19 21:53:09 - newser.com
Can Oruka Therapeutics Inc. (HQ1) stock surprise with quarterly resultsPortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Can Oruka Therapeutics Inc. stock sustain market leadershipEarnings Trend Report & Weekly Breakout Watchlists - newser.com
Published on: 2025-11-19 17:15:05 - newser.com
Key metrics from Oruka Therapeutics Inc.’s quarterly dataPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Can momentum traders help lift Oruka Therapeutics Inc.July 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock sustain dividend payoutsWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock attract long term capital inflowsDividend Hike & Safe Capital Growth Tips - newser.com
Why Oruka Therapeutics Inc. (HQ1) stock is trending on social mediaQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliableJuly 2025 Outlook & Safe Capital Preservation Plans - newser.com
Tools to monitor Oruka Therapeutics Inc. recovery probability2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Is Oruka Therapeutics Inc. stock supported by strong cash flows2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Oruka Therapeutics Reports Q3 2025 Financial Results - TipRanks
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Research Analysts Issue Forecasts for ORKA FY2025 Earnings - Defense World
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):